RxDoctor Payments Data

John Wideman, MD

Obstetrics & Gynecology · Cullman, ALNPI 1336255728

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $2,947 of the $3,639 with a category attached, or 81.0%. 34 manufacturers reported payments, led by Pfizer at 41.4% of the total. Reporting peaked in 2019 at $1,638 and has fallen 88.5% since, to $189 in 2025.

$3,639in general payments, 2019–2025

Across 130 payments — averaging $27.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$2K
  • AbbVie$455
  • Shield Therapeutics Inc$245
  • Aspira Women's Health Inc$216
  • Amgen$125
  • Myriad Women's Health, Inc.$117
  • plus $977 from 28 others
$2,267,491in research payments, 2019–2025

Across 97 payments — averaging $23,376 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Pfizer$2.3M

What the payments were for

  • Travel & lodging$59816%
  • Food & beverage$2,94781%
  • Education$832%
  • Gifts$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,639 in reported general payments places this provider in the 75th percentile of 537 obstetrics & gynecology providers in Alabama.

See all obstetrics & gynecology providers in Alabama

Medicare billing

Part B allowed, 2024
$9,703
Medicare patients
39
Services billed
73

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
PremarinEstrogens, Conjugated21$8,923
Estradiol101$4,175
Estradiol (Twice Weekly)Estradiol24$2,514
Estradiol (Once Weekly)Estradiol23$1,641
Fluconazole27$253
Oxybutynin Chloride11$222
Acyclovir16$145
Zolpidem Tartrate12$117
Fluoxetine Hcl15$100

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerPremarin$1,505$8,92321 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 537 obstetrics & gynecology providers in Alabama.

Other obstetrics & gynecology in Cullman

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →